Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSA17 is a bile acid derivative.1 It reduces triglyceride accumulation induced by oleic acid (Item Nos. 90260 | 24659), increases cell viability, and decreases oleic acid-induced lipid peroxidation in primary rat hepatocytes when used at concentrations of 10 and 25 µM. A17 (25 µM) reduces levels of CD36, also known as scavenger receptor B2 or fatty acid translocase, in primary rat hepatocytes. In vivo, A17 (50 mg/kg) reduces serum triglyceride, total cholesterol, and LDL levels, reverses hepatic steatosis, and decreases hepatic triglyceride, but not total cholesterol, levels in a hamster model of high-fat diet-induced non-alcoholic steatohepatitis (NASH).
WARNING This product is not for human or veterinary use.
1. A novel bile acid analog, A17, ameliorated non-